Treatment of Pulmonary Hydatid Disease When Surgery Is Not Feasible

Not every patient with pulmonary hydatid disease (echinococcosis of the lung) is a surgical candidate. A defined set of clinical situations calls for a non-operative approach — and a structured, evidence-based treatment protocol applies to each of them.

Clinical Situations Covered by This Protocol

Small cysts
High surgical risk
Refusal of surgical treatment
Multiorgan failure
Multiple cysts
Intraoperative spillage of hydatid fluid

Treatment Approach

In these situations, medical (pharmacological) therapy is indicated. Treatment centres on an oral anthelminthic agent taken with food to maximise absorption, combined with mandatory laboratory monitoring throughout the course.

The complete regimen — agent, dosing schedule, duration, and monitoring protocol — is available in the full structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.5152/eurasianjmed.2025.24761

Indications for medical treatment of pulmonary hydatid cysts include small cysts, high surgical risk, refusal of surgical treatment, multiorgan failure, multiple cysts, and patients with intraoperative spillage of hydatid fluid.

Albendazole is administered to prevent postoperative recurrence and for treatment in cases where surgery is not feasible.

Albendazole is the most preferred drug worldwide due to its better bioavailability, higher efficacy, and lower required dosage compared to mebendazole.

Monitoring of liver enzymes and complete blood count during treatment is mandatory, starting at weekly intervals at the start of treatment and continuing monthly and at longer intervals after stabilization.

View source ↗